Bristol Myers Squibb’s Mavacamten, an oral drug, becomes the first cardiac myosin inhibitor that has been approved by the US
Continue readingDay: April 29, 2022
Researchers from Boston Children Hospital and Yonsei University created AI model to predict no-shows
Researchers from Boston Children’s Hospital and Yonsei University created an AI Model-a machine learning tool- to predict no-shows at appointments
Continue readingUCM and Empress EMS team up to provide virtual and hands-on medical care to limit in person visits
UCM Digital Health, a firm that provides telehealth facilities of triage and support to patients, has entered into a partnership
Continue readingThe beverage giant, Frucor Suntory, plans to build a $400 million manufacturing plant in Australia
Frucor Suntory, the beverage giant, has planned to invest $400 million to build a new manufacturing plant in Ipswich, Queensland.
Continue readingJBS launched its new electric-powered truck rental business: No Carbon
A global supplier of processed meat, chicken and beef products, JBS, has rolled out its new business titled No Carbon.
Continue readingJapanese cosmetics brand, Shiseido, tests its unpaid YouTube series
Shiseido, a Japanese cosmetic brand, is currently experimenting with its unpaid YouTube series. The brand aims to eventually develop a
Continue readingRoz Brewer, Walgreens CEO, reveals an essential component that can make firms stand out
Walgreens Boots Alliance CEO Roz Brewer has recently shared valuable insights on how one particular component can set corporations apart.
Continue reading3% year-over-year (YoY) drop in global online sales, Salesforce shopping data reveals
Salesforce, an American cloud-based software company, published its digital retail shopping trends in Q1 of 2022. The report exhibited a
Continue readingHow automated ads are helping these three brands scale up their online businesses
As consumers increasingly shop and stay online, brands need to use marketing automation tools to utilise machine learning. Almost 80%
Continue readingFDA approves AstraZeneca’s Ultomiris for the 3rd time
AstraZeneca’s Ultomiris has been approved by the FDA for the treatment of neurological disorders in the past. However, it has
Continue reading
English